Seqster Launches MyAlzheimer's Patient Registry
Tool targets advanced drug monitoring and safety—and enables access to real-world data.
Seqster PDM, a healthcare technology company, has officially launched MyAlzheimer's Patient Registry, which allows patients and caregivers to manage their health data, access new treatment options, and participate in clinical trials in a secure and centralized registry. The platform also enables researchers to access real-world patient data to aid in developing new treatments and gain a deeper understanding of Alzheimer's disease.
MyAlzheimer's features the ability for patients to grant consent for their data to be used for research purposes, including participation in clinical trials. Caregivers can use the registry to coordinate care and manage medication schedules.
MyAlzheimer's Patient Registry is built on the Seqster operating system, connected to over 5,000 healthcare systems and 150,000 healthcare provider sources.
Reference: Seqster Launches MyAlzheimer's Patient Registry for Advanced Drug Monitoring & Safety, May 9, 2023, San Diego, CA.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
